Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70172 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867010923429888000 |
|---|---|
| author | Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway |
| author_facet | Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway |
| collection | Wiley Open Access |
| contents | Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway Clinical Transplantation ABSTRACT Belatacept (BELA) pharmacokinetic (PK) studies informed dosing strategies used in phase 3 studies, where fixed mg/kg dosing compared a less intensive (LI) and more intensive (MI) regimen. The LI regimen was preferred due to a better risk/benefit profile. We compared PK parameters observed in the BELA Early Steroid Withdrawal Trial (BEST) with previous reports. BELA trough samples were analyzed using a validated quantitative enzyme‐linked immunoassay. Clearance (CL) was estimated with Bayesian estimation using a published BELA population PK model. Significantly higher CL was observed in subjects <60 years old and African American (AA) patients, leading to decreased BELA exposure. No differences in allometrically scaled CL were observed by BMI or sex; however, overall BELA exposure was greater in males. There were no differences in exposure in subjects with rejection; however, subjects with infection had significantly higher exposure. BELA PK was not different between alemtuzumab and rabbit‐antithymocyte globulin induction groups without steroids, but overall drug exposure was higher than previously reported in trials co‐administering with basiliximab and steroids. Future studies to optimize BELA dosing strategies are warranted as BELA exposure in this analysis exceeded Phase 3 target thresholds. Trial Registration : ClinicalTrials.gov identifier: NCT 01729494 10.1111/ctr.70172 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.70172 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_70172 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway Clinical Transplantation Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis Alexandra Pyatt Melissa McGowan Ryota Tanaka Bradley Miyagawa Tomoyuki Mizuno Adele Rike Shields Annette Christianson Patricia West‐Thielke John P. Leone E. Steve Woodle Dixon Kaufman Alexander Wiseman Arthur J. Matas Alexander A. Vinks Rita R. Alloway Clinical Transplantation ABSTRACT Belatacept (BELA) pharmacokinetic (PK) studies informed dosing strategies used in phase 3 studies, where fixed mg/kg dosing compared a less intensive (LI) and more intensive (MI) regimen. The LI regimen was preferred due to a better risk/benefit profile. We compared PK parameters observed in the BELA Early Steroid Withdrawal Trial (BEST) with previous reports. BELA trough samples were analyzed using a validated quantitative enzyme‐linked immunoassay. Clearance (CL) was estimated with Bayesian estimation using a published BELA population PK model. Significantly higher CL was observed in subjects <60 years old and African American (AA) patients, leading to decreased BELA exposure. No differences in allometrically scaled CL were observed by BMI or sex; however, overall BELA exposure was greater in males. There were no differences in exposure in subjects with rejection; however, subjects with infection had significantly higher exposure. BELA PK was not different between alemtuzumab and rabbit‐antithymocyte globulin induction groups without steroids, but overall drug exposure was higher than previously reported in trials co‐administering with basiliximab and steroids. Future studies to optimize BELA dosing strategies are warranted as BELA exposure in this analysis exceeded Phase 3 target thresholds. Trial Registration : ClinicalTrials.gov identifier: NCT 01729494 10.1111/ctr.70172 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT‐EXT Pharmacokinetic Analysis |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70172 |